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Objectives. This study sought to investigate the relations be-
tween plasma antioxidant status, extent of atherosclerosis and
activity of coronary artery disease.
Background. Previous studies indicate that increased antioxi-
dant intake is associated with decreased coronary disease risk, but
the underlying mechanisms remain controversial.
Methods. Plasma samples were obtained from 149 patients
undergoing cardiac catheterization (65 with stable angina, 84 with
unstable angina or a myocardial infarction within 2 weeks).
Twelve plasma antioxidant/oxidant markers were measured and
correlated with the extent of atherosclerosis and the presence of
an unstable coronary syndrome.
Results. By multiple linear regression analysis, age (p < 0.001),
diabetes mellitus (p < 0.001), male gender (p < 0.001) and
hypercholesterolemia (p 5 0.02) were independent predictors of
the extent of atherosclerosis. No antioxidant/oxidant marker
correlated with the extent of atherosclerosis. However, lower
plasma ascorbic acid concentration predicted the presence of an
unstable coronary syndrome by multiple logistic regression (odds
ratio [OR] 0.59, 95% confidence interval [CI] 0.40 to 0.89, p 5
0.01). The severity of atherosclerosis also predicted the presence
of an unstable coronary syndrome (OR 1.7, 95% CI 1.14 to 2.47,
p 5 0.008) when all patients were considered. When only patients
with significant coronary disease were considered (at least one
stenosis >50%), ascorbic acid concentration (OR 0.56, 95% CI
0.37 to 0.85, p 5 0.008) and total plasma thiols (OR 0.52, 95% CI
0.34 to 0.80, p 5 0.004) predicted the presence of an unstable
coronary syndrome, whereas the extent of atherosclerosis did not.
Conclusions. These data are consistent with the hypothesis that
the beneficial effects of antioxidants in coronary artery disease
may result, in part, by an influence on lesion activity rather than
a reduction in the overall extent of fixed disease.
(J Am Coll Cardiol 1998;31:980–6)
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Prospective studies have demonstrated reduced risk of coro-
nary artery disease in subjects with a greater intake of vitamin
E (1,2) or ascorbic acid (3). Because these antioxidant vitamins
inhibit oxidation of low density lipoprotein (LDL), a critical
event in the pathogenesis of atherosclerosis, investigators have
speculated that they reduce coronary artery disease by limiting
the development or progression of atherosclerotic lesions.
However, studies examining this issue have provided conflict-
ing results (4–8). It has recently become apparent that anti-
oxidants may favorably influence coronary artery disease
through alternative mechanisms, including improvement of
endothelial function (9,10), inhibition of platelet aggregability
(11) and a decrease in the risk of plaque rupture (12) (see Diaz
et al. [8] for review). The clinical relevance of these alternative
mechanisms is supported by the finding that vitamin E treat-
ment reduces nonfatal myocardial infarction in patients with
coronary disease after only 200 days of follow-up (13), a time
span that is most likely too short for significant lesion regres-
sion.
It is difficult to assess the effect of antioxidants on lesion
progression or regression and the relevance of such effects to
primary or secondary prevention of coronary events in the
available larger studies (1–3) because angiography was not
performed. These studies are further limited because antioxi-
dant levels were not directly measured. In smaller studies,
increased LDL susceptibility to oxidation (14) and decreased
LDL alpha-tocopherol content (15) have been shown to cor-
relate with the angiographic extent of atherosclerosis. Leuko-
cyte ascorbic acid concentration correlates inversely with the
angiographically determined extent of coronary atherosclerosis
(16). The presence of angina pectoris also correlates with lower
alpha-tocopherol and ascorbic acid concentrations (17). In a
recent prospective population study, a low plasma ascorbic
acid level was associated with an increased risk of myocardial
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infarction (18). Thus, the available evidence suggests impor-
tant links between coronary atherosclerosis, clinical symptoms
of coronary artery disease and impaired antioxidant defenses.
However, no previous study has related antioxidant status to
both coronary artery disease extent and coronary disease
activity. Therefore, this study sought to make such a compar-
ison and determine whether antioxidant status relates indepen-
dently to clinical symptoms of coronary artery disease.
Methods
Patients. Consecutive patients referred to the Boston
Medical Center for cardiac catheterization were enrolled as
required by the institutional review board. A 30-ml fasting
blood sample was obtained at the time of catheterization.
A research nurse noted the presence of the following risk
factors: 1) age; 2) male gender; 3) clinical history of diabetes
(fasting blood glucose .140 mg/dl or treatment with insulin or
an oral hypoglycemic agent); 4) clinical history of hypertension
(blood pressure .90 mm Hg diastolic or treatment for hyper-
tension); 5) clinical history of hypercholesterolemia (total
cholesterol .200 mg/dl or previous drug treatment for hyper-
cholesterolemia); 6) cigarette smoking (total pack-years and
time since last cigarette); and 7) family history of coronary
disease (first-degree relative with myocardial infarction or
cardiac death before age 55). Patients were also questioned
about medications, multivitamin use and minority status. Total
cholesterol, high density lipoprotein (HDL) and triglycerides
were measured in the hospital clinical laboratory. LDL choles-
terol was calculated using the Friedewald formula (19).
Assessment of extent of coronary atherosclerosis. Coro-
nary angiograms were analyzed off-line in a blinded manner.
The extent of atherosclerosis was quantified using the “Ham-
sten extent score” (20), which reflects the extent of early
coronary atherosclerosis and is expressed on a scale of 0 (no
disease) to 9 (extensive disease in each of 15 coronary seg-
ments). The extent of advanced coronary disease was assessed
by measuring stenosis severity using digital calipers. For each
patient, the “global stenosis score” was calculated as described
by Regnstro¨m et al. (15). In this score, the severity of stenoses
is assessed in each of 15 coronary segments, and the severity of
atherosclerosis is expressed on a scale of 0 (no stenoses .25%)
to 16 (multiple advanced stenoses or occlusions in all 15
segments).
Assessment of clinical activity of coronary disease. We
obtained a detailed angina history and reviewed the medical
record for evidence of unstable angina as defined by Braun-
wald (21) or myocardial infarction as indicated by the presence
of typical symptoms, ischemic electrocardiographic changes
and a diagnostic elevation of creatine kinase, MB fraction
(CK-MB). It is currently understood that unstable angina and
acute myocardial infarction have a common pathophysiology
(plaque rupture and consequent intracoronary thrombosis)
(22). Therefore, we categorized each patient as having or not
having an unstable coronary syndrome (unstable angina or
myocardial infarction within 2 weeks of study).
Assessment of antioxidant/oxidant status. Blood samples
were immediately transferred into Vacutainer tubes containing
heparin (286 U/15 ml blood) (Becton Dickinson), placed on ice
and protected from light. Within 2 h of collection, plasma was
prepared at 4°C, and samples were processed or frozen at
270°C, as appropriate.
For assessment of LDL resistance to oxidation, LDL was
isolated from plasma within 2 h of collection (23), and LDL
resistance to oxidation was determined by incubating LDL
(0.1 mg LDL protein/ml) with 3.3 mmol/liter CuCl2 at 37°C and
assaying lipid peroxidation as diene conjugation. LDL resis-
tance to oxidation was quantified as the lag phase duration (in
minutes) before the propagation phase of diene conjugation
(23). Levels of LDL alpha-tocopherol and plasma alpha-
tocopherol, beta-carotene, gamma-tocopherol and retinol
were determined from frozen samples by reversed-phase high
performance liquid chromatography (HPLC), as previously
described (24). Ascorbic acid and uric acid concentrations in
metaphosphoric acid-precipitated plasma were determined by
HPLC with electrochemical detection (25). Total plasma thiols
were determined by 5,59-dithiobis(2-nitrobenzoic acid) (26).
The plasma concentration of free F2-isoprostanes, a stable
marker of lipid peroxidation, was measured using a stable
isotope dilution mass spectrometric assay (27). Plasma cerulo-
plasmin was determined by its oxidase activity using
o-dianisidine dihydrochloride (Sigma), as previously described
(28). Erythrocyte copper–zinc superoxide dismutase activity
was determined as previously described (29).
Statistical analysis. First, univariate analysis was per-
formed to examine the relations between the extent of athero-
sclerosis, antioxidant/oxidant markers and standard coronary
risk factors. The Hamsten extent score (20) was correlated with
each of 12 antioxidant/oxidant markers (Table 1) and seven
coronary risk factors (age, male gender, history of diabetes
mellitus, history of hypertension, history of hypercholesterol-
emia, cigarette smoking [pack-years] and family history of
premature coronary disease). Normal distribution of the Ham-
sten extent score and each antioxidant/oxidant marker was
confirmed using the Kolmogorov-Smirnov algorithm. We also
examined the relation between selected antioxidant markers
and coronary risk factors using two-sample t tests or the
chi-square test for continuous and categoric variables, respec-
tively. The univariate analysis was also repeated using the
global stenosis score (15).
To identify independent predictors of the extent of coro-
nary atherosclerosis, all variables with a univariate p value ,
Abbreviations and Acronyms
CI 5 confidence interval
CK 5 creatine kinase
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
HPLC 5 high pressure liquid chromatography
OR 5 odds ratio
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0.10 were then included in a multivariate analysis. Independent
predictors of the Hamsten extent score were identified using
stepwise linear regression analysis. The threshold p , 0.10 for
inclusion in the analysis was selected because it has been
recommended for detecting important predictive factors with-
out including unimportant nonpredictors (30,31).
For clinical activity of coronary artery disease, patients were
categorized as having or not having an unstable coronary
syndrome on the basis of the presence or absence of unstable
angina or a myocardial infarction within 2 weeks of the study.
Antioxidant/oxidant markers, coronary risk factors and the
extent of atherosclerosis were compared for the two groups
using two-sample t tests or the chi-square test for continuous
and categoric variables, respectively. The variables with a
univariate p value , 0.10 were then included in a multivariate
analysis using multiple logistic regression to identify indepen-
dent predictors of the presence of an unstable coronary
syndrome. The ability to predict an unstable coronary syn-
drome was expressed as the odds ratio with the 95% confi-
dence interval for an increase of 1 SD in the variable.
All analyses were completed using SPSS for Windows,
Release 6.0. Statistical significance was defined as p , 0.05.
Unless otherwise indicated, all results are expressed as mean
value 6 SD.
Results
Patients. A total of 149 patients were enrolled in the study.
The demographic profile, distribution of coronary risk factors
and lipoprotein profile are presented in Table 1. The racial
distribution of the patients was 137 white, 9 African American
and 3 Hispanic. Regarding medications, 140 (94%) were taking
some form of antianginal therapy (beta-adrenergic blocking
agent, calcium channel blocking agent or nitrate); 128 (86%)
were taking aspirin; 39 (26%) were receiving lipid-lowering
therapy; 31 (21%) were taking an angiotensin-converting en-
zyme inhibitor; 4 (3%) were taking vitamin E supplements; 3
(3%) were taking ascorbic acid supplements; and 6 (4%) were
taking multivitamins. The mean Hamsten extent score was
3.2 6 1.9 (range 0.0 to 8.2), and the mean global stenosis score
was 1.65 6 1.45 (0 to 7.1). Twenty-one patients had normal
coronary arteries or minimal coronary disease; 33 had one-
vessel disease (.50% stenosis); 42 had two-vessel disease; and
53 had three-vessel disease. The Hamsten extent score corre-
Table 1. Univariate Predictors of Extent of Atherosclerosis in 149 Patients
Mean (6SD) or
No. (%) of Pts r*
p
Value
Coronary risk factors
Age (yr) 62 6 12 0.33 0.001
Male gender 87 (58%) 0.24 0.005
Diabetes mellitus 36 (24%) 0.26 0.002
Hypertension 85 (57%) 0.21 0.01
Hypercholesterolemia 81 (54%) 0.20 0.02
Smoking (pack-years) 31 6 33 0.05 0.57
Family history of premature CAD 61 (41%) 0.01 0.87
Lipid profile
Total cholesterol (mg/dl) 202 6 37 20.04 0.66
HDL cholesterol (mg/dl) 39 6 12 20.001 0.99
Triglycerides (mg/dl) 153 6 81 20.06 0.52
Calculated LDL (mg/dl) 134 6 35 20.04 0.62
Lipid-soluble antioxidants
Alpha-tocopherol (mmol/liter) (n 5 146) 19.8 6 14.3 20.01 0.93
Beta-carotene (mmol/liter) (n 5 41) 0.39 6 0.30 0.02 0.92
Gamma-tocopherol (mmol/liter) (n 5 60) 5.4 6 3.3 0.03 0.83
Retinol (mmol/liter) (n 5 41) 1.5 6 0.4 20.22 0.17
LDL alpha-tocopherol
(nmol/mg protein) (n 5 41)
4.1 6 1.4 0.03 0.87
Water-soluble antioxidants
Ascorbic acid (mmol/liter) (n 5 143) 37.5 6 19.5 0.02 0.85
Uric acid (mmol/liter) (n 5 144) 312 6 92 0.05 0.54
Total plasma thiols (mmol/liter) (n 5 147) 241 6 70 20.06 0.48
Other markers
Ceruloplasmin (U/liter) (n 5 62) 112 6 31 20.09 0.48
Erythrocyte SOD (U/mg protein) (n 5 41) 0.23 6 0.14 20.02 0.92
LDL oxidation lag phase (min) (n 5 41) 68 6 18 20.15 0.35
F2-isoprostanes (pg/ml) (n 5 54) 43.4 6 38.5 0.06 0.66
*Correlation coefficient for relation with Hamsten extent score (see text). CAD 5 coronary artery disease; HDL 5
high density lipoprotein; LDL 5 low density lipoprotein; Pts 5 patients; SOD 5 superoxide dismutase.
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lated with the global stenosis score (r 5 0.78, p , 0.0001). A
total of 58 patients (39%) had unstable angina as defined by
Braunwald (21), and 26 (17%) had a myocardial infarction
within 2 weeks of the study; thus, 65 patients were classified as
clinically stable, and 84 were classified as having an unstable
coronary syndrome.
Antioxidant/oxidant status. The results of the assessment
of plasma antioxidant status for the entire cohort are shown in
Table 1. Patients with a history of cigarette smoking (n 5 115
[77%]) had lower ascorbic acid concentrations (34.6 6 18.5
mmol/liter) than those who never smoked (47.5 6 20.1 mmol/
liter, p 5 0.001). Furthermore, patients with a history of
smoking within 1 week of the study (n 5 35 [24%]) had lower
ascorbic acid concentrations (28.4 6 18.7 mmol/liter) than
smokers who had not smoked within 1 week of the study
(37.3 6 17.8 mmol/liter, p , 0.05). The lag phase of LDL
oxidation was shorter in diabetic (60 6 11 min) than in
nondiabetic patients (74 6 20 min, p 5 0.02). Patients with a
history of hypertension also had a shorter lag phase (61 6
13 min) than nonhypertensive patients (75 6 20 min, p 5
0.008).
The ascorbic acid concentration in patients with a history of
myocardial infarction within 2 weeks of the study (31.8 6 14.8
mmol/liter) was not different from that in patients with unsta-
ble angina but no recent myocardial infarction (34.4 6 17.5,
p 5 0.52). This finding argues against the possibility that
myocardial infarction causes a fall in ascorbic acid concentra-
tion in this cohort, as has been previously reported (32–34). No
significant differences were observed for any other plasma
antioxidant/oxidant markers in patients with and without a
history of tobacco use, diabetes mellitus or hypertension.
Predictors of extent of atherosclerosis. As presented in
Table 1, age, hypercholesterolemia, diabetes mellitus, hyper-
tension and male gender were significant univariate correlates
of the Hamsten extent score. No other variables met the
criteria for entry into the multivariate analysis (p , 0.10), and
as presented in Table 2, the independent predictors of the
extent of atherosclerosis were age, diabetes mellitus, hypercho-
lesterolemia and male gender (multiple r2 5 0.58, p , 0.0001).
No antioxidant/oxidant marker correlated significantly with
this measure of coronary atherosclerosis extent. As detailed in
Table 1, not every antioxidant marker was examined in every
patient. For alpha-tocopherol, ascorbic acid and total thiols,
the study provided 80% power to demonstrate statistical
significance at the p , 0.05 level if the univariate correlation
coefficient was .0.22.
Because a recent study (15) indicated a correlation between
LDL alpha-tocopherol and global stenosis score, the univariate
analysis was repeated using this measure of more advanced
coronary atherosclerosis. A history of diabetes mellitus (r 5
0.30, p 5 0.0001), age (r 5 0.28, p 5 0.0006) and male gender
(r 5 0.21, p 5 0.007) correlated with global stenosis score, but
antioxidant/oxidant markers did not, including plasma alpha-
tocopherol (r 5 20.02, p 5 0.83) and LDL alpha-tocopherol
(r 5 20.09, p 5 0.56). Cholesterol-adjusted alpha-tocopherol,
which was calculated as the ratio of alpha-tocopherol to total
cholesterol concentration, also did not correlate with the
Hamsten extent score (r 5 20.03, p 5 0.77) or global stenosis
score (r 5 20.01, p 5 0.99).
Predictors of an unstable coronary syndrome. As pre-
sented in Table 3, the significant univariate predictors of an
unstable coronary syndrome were pack-years, lower ascorbic
acid concentration and extent of atherosclerosis. The other
variables that met criteria for entry into the multivariate
Table 3. Characteristics of Patients With and Without an Unstable
Coronary Syndrome
Stable
(n 5 65)
Unstable
(n 5 84)
p
Value
Coronary risk factors
Age (yr) 61 6 12 63 6 13 0.46
Family Hx of CAD 28 (43%) 33 (40%) 0.68
Hx of diabetes mellitus 15 (23%) 21 (25%) 0.79
Hx of hypertension 32 (49%) 53 (63%) 0.09
Hx of hypercholesterolemia 31 (48%) 37 (44%) 0.66
Smoking Hx (pack-years) 24 6 27 35 6 35 0.04
Smoking within 1 wk of study 12 (19%) 23 (27%) 0.20
Male gender 32 (49%) 55 (66%) 0.05
Lipid-soluble antioxidants
Alpha-tocopherol (mmol/liter) 22.2 6 16.1 18.0 6 12.4 0.08
Beta-carotene (mmol/liter) 0.36 6 0.28 0.43 6 0.33 0.44
Gamma-tocopherol (mmol/liter) 5.6 6 3.0 5.3 6 3.6 0.72
Lycopene (mmol/liter) 0.93 6 0.50 1.00 6 0.56 0.70
Retinol (mmol/liter) 1.6 6 0.3 1.5 6 0.5 0.43
LDL alpha-tocopherol
(nmol/mg protein)
4.2 6 1.5 4.0 6 1.4 0.61
Water-soluble antioxidants
Ascorbic acid (mmol/liter) 42.5 6 21.8 33.6 6 16.7 0.007
Uric acid (mmol/liter) 297 6 84 323 6 96 0.10
Total plasma thiols (mmol/liter) 253 6 74 231 6 66 0.07
Other markers
Ceruloplasmin (U/liter) 108 6 34 115 6 29 0.39
Erythrocyte SOD (U/mg protein) 0.25 6 0.17 0.21 6 0.09 0.31
LDL oxidation lag phase (min) 71 6 18 66 6 18 0.38
F2-isoprostanes (pg/ml) 47.1 6 34.6 40.4 6 41.6 0.53
Atherosclerosis extent*
Hamsten extent score 2.6 6 1.9 3.6 6 1.8 0.004
Global stenosis score 1.2 6 1.3 2.0 6 1.5 0.001
*See text for definition of Hamsten extent and Global stenosis scores.
Abbreviations as in Tables 1 and 2.
Table 2. Multivariate Analysis for Predictors of Extent
of Atherosclerosis
Adjusted
r Value
Multivariate
p Value
Included in model
Age 0.44 0.0001
Hx of hypercholesterolemia 0.17 0.02
Hx of diabetes mellitus 0.27 0.0002
Male gender 0.36 0.0001
Excluded from model
Hx of hypertension 0.06 0.47
*Multiple r2 value for model 5 0.58, p , 0.0001. Hx 5 history.
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analysis (p , 0.10) were male gender, history of hypertension,
lower alpha-tocopherol concentration and lower plasma thiols.
The independent predictors of an unstable coronary syndrome
were a low ascorbic acid level (odds ratio [OR] 0.59, 95%
confidence interval [CI] 0.40 to 0.89, p 5 0.01) and the
Hamsten extent score (OR 1.7, 95% CI 1.14 to 2.47, p 5
0.008).
Because ascorbic acid levels have been reported to be low
immediately after an acute myocardial infarction (32,34), the
analysis was repeated excluding the 26 patients with a history
of myocardial infarction within 2 weeks of study. In this
analysis, a low ascorbic acid concentration (OR 0.63, 95% CI
0.40 to 0.98, p 5 0.04) and the Hamsten extent score (OR 2.0,
95% CI 1.3 to 3.1, p 5 0.003) remained independent predictors
of an unstable coronary syndrome (unstable angina).
Because patients without significant coronary disease are
unlikely to have an unstable coronary syndrome, and because
antioxidant treatment is known to have beneficial effects on
vascular function (9,10) and coronary events in patients with
established coronary artery disease (13), we also examined the
relation between antioxidant status and coronary disease ac-
tivity in the subset of patients with at least one coronary artery
stenosis .50% (n 5 128). In this group of patients, a low
plasma ascorbic acid concentration (OR 0.56, 95% CI 0.37 to
0.85, p 5 0.008) and low plasma thiols (OR 0.52, 95% CI 0.34
to 0.80, p 5 0.004) were independent predictors of an unstable
coronary syndrome, whereas the Hamsten extent score and
global stenosis score were not.
Discussion
In the present study, we evaluated the extent of coronary
atherosclerosis, the clinical activity of coronary artery disease,
coronary risk factors and 12 markers of plasma antioxidant/
oxidant status in patients referred for cardiac catheterization.
The extent of coronary atherosclerosis correlated indepen-
dently with several established risk factors for coronary disease
(older age, diabetes mellitus, hypercholesterolemia and male
gender) but not with any marker of antioxidant/oxidant status.
Although antioxidant/oxidant status failed to predict athero-
sclerosis extent, a lower plasma ascorbic acid concentration did
predict coronary disease activity (the presence of unstable
angina or acute myocardial infarction). When the entire group
of patients with and without coronary atherosclerosis was
considered, we observed that the extent of atherosclerosis also
predicted the presence of an acute coronary syndrome. How-
ever, when only patients with at least one coronary stenosis
.50% were considered, two markers of antioxidant status (low
plasma ascorbic acid and thiols) predicted the presence of an
unstable coronary syndrome, whereas the extent of atheroscle-
rosis did not. These associations could not be explained by the
presence of recent myocardial infarction and were indepen-
dent of the assessed risk factors and antioxidant markers,
including previous or recent cigarette smoking, which may
have a direct effect on ascorbic acid level. These findings
support the hypothesis that antioxidant status may influence
coronary artery disease through an effect on lesion activity
rather than by a reduction of the overall extent of fixed disease.
Antioxidants and atherogenesis. The idea that antioxi-
dants might prevent coronary events by limiting lesion forma-
tion is based on emerging evidence linking oxidation of LDL to
human atherogenesis (14,35) and atherosclerosis progression
(36). Because vitamins E and C can limit LDL oxidation (37),
one would expect that increased availability of these antioxi-
dant vitamins would slow the atherosclerotic process. In sup-
port of this hypothesis, previous studies have shown that 1) the
severity of carotid atherosclerosis correlates inversely with
dietary ascorbic acid and vitamin E intake (7); 2) the extent of
coronary atherosclerosis correlates inversely with LDL alpha-
tocopherol content (15); and 3) increased vitamin E intake in
combination with lipid-lowering therapy is associated with less
progression of coronary atherosclerosis (5). However, in other
studies the relation between antioxidant status and lesion
severity is less clear. For example, Hodis et al. (5) reported less
progression of coronary atherosclerosis in patients with higher
vitamin E intake, but the effect of vitamin E was modest
(regression in mean stenosis severity of 0.8% vs. progression of
2.0% over 2 years) and was limited to the subgroup of patients
receiving lipid-lowering therapy. In the only available prospec-
tive, placebo-controlled trial examining this issue (6), probucol
(a potent synthetic antioxidant) had no effect on femoral artery
lesion severity, although interpretation of this finding is com-
plicated by a reduction in HDL cholesterol with probucol
treatment.
In the current study, we observed no significant correlation
between any of the measured markers of plasma antioxidant/
oxidant status and extent of coronary atherosclerosis. This
finding contrasts with the work of Regnstro¨m et al. (14), who
reported a significant correlation between LDL oxidation lag
phase and the extent of early atherosclerosis (Hamsten extent
score). In a more recent study by the same group (15), LDL
alpha-tocopherol and lipid-adjusted alpha-tocopherol corre-
lated with the extent of atherosclerosis (global stenosis score),
whereas LDL oxidation lag phase did not. The reason for these
apparent discrepancies is unclear but may relate to differences
in study patients. Those two previous studies examined young
men who were clinically stable several months after their first
myocardial infarction and a larger group of normal patients,
whereas our study examined older patients with more ad-
vanced disease and both stable and unstable symptoms.
Antioxidants and coronary disease activity. In contrast to
the lack of significant correlation between disease extent and
antioxidant/oxidant status, our study demonstrated a strong
independent association between low plasma ascorbic acid
concentration and a recent unstable coronary syndrome. In the
patients with significant coronary artery disease, low plasma
thiols were also predictive of an unstable coronary syndrome.
Several previous studies also support the importance of anti-
oxidant status in the clinical activity of coronary disease. A
prospective population study (18) demonstrated that Finnish
men with ascorbic acid deficiency (,11.4 mmol/liter) have an
increased risk of myocardial infarction. In another study (17),
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lower plasma levels of ascorbic acid and cholesterol-adjusted
alpha-tocopherol correlated with angina, although the corre-
lation between ascorbic acid and angina was lost after adjust-
ment for the effect of smoking on ascorbic acid concentration.
We also observed lower ascorbic acid concentrations in smok-
ers, but in our study, the correlation of ascorbic acid with
angina was independent of smoking as well as other risk
factors. One previous study (38) also demonstrated an associ-
ation of lower plasma levels of reduced thiols with unstable
angina.
It is interesting that coronary disease activity relates to the
plasma concentrations of these two important water-soluble
antioxidant species. Ascorbic acid is known to be the most
effective water-soluble antioxidant in plasma (25). As was
recently suggested by Levine et al. (39), some previous studies
(1) may have failed to detect an association between coronary
disease and ascorbic acid intake because they failed to examine
a sufficiently low intake level, given that tissue stores are
saturated with a daily intake of only 100 mg/day (39). Thiol
species also act as antioxidants in plasma (25), and intracellu-
larly, the thiol compound glutathione is the predominant low
molecular weight antioxidant species that acts in concert with
ascorbic acid to regulate cellular redox status (40). Thus, a
deficiency of thiols or ascorbic acid is likely to have important
implications for arterial homeostasis.
The precise mechanisms of how decreased plasma antioxi-
dant levels could be associated with more severe symptoms or
unstable coronary syndromes independent of an effect on
atherosclerosis extent remain controversial. It is currently
recognized that acute coronary syndromes occur after activa-
tion of atherosclerotic lesions, a process that leads to plaque
rupture, thrombosis and vasospasm (22). Other interventions
that have been clearly shown to reduce coronary artery disease
risk, such as lipid-lowering therapy, most likely act in large part
by inhibiting these processes (41). There is growing evidence
that increased oxidative stress and impaired antioxidant pro-
tection are relevant to plaque activation and the other events
associated with acute coronary syndromes (8). For example,
oxidized LDL stimulates expression of adhesion molecules and
impairs effective release of nitric oxide, leading to accumula-
tion of leukocytes in the vessel wall and thus promotes plaque
rupture (12,42,43). Furthermore, oxidized LDL induces ex-
pression of prothrombotic factors, such as plasminogen activa-
tor inhibitor-1 and tissue factor, and thus increases the risk of
coronary thrombosis (8,12). By inhibiting nitric oxide action,
oxidized LDL also promotes platelet adhesion and vasospasm.
By opposing formation of oxidized LDL, antioxidants may
limit all these processes (8,12,43).
In addition to limiting LDL oxidation, antioxidants may
further oppose acute coronary events by direct effects on
vascular cell function. Such effects include increased resistance
to the cytotoxic effects of oxidized LDL, decreased production
of reactive oxygen species and increased effective production
of nitric oxide (8,43). In human studies, lipid-soluble antioxi-
dants have been shown to inhibit platelet aggregation (11) and
improve endothelium-dependent vasomotor function (10).
Furthermore, ascorbic acid treatment acutely improves endo-
thelial nitric oxide action in patients with coronary artery
disease (9) and decreases monocyte adhesiveness to endothe-
lial cells in cigarette smokers (44). Ascorbic acid may also
increase prostacyclin production (45) and lower blood pressure
(46). There also is growing evidence that thiol status impor-
tantly regulates nitric oxide bioactivity (47). The findings of the
present study demonstrating an inverse association between
plasma thiol and ascorbic acid concentrations and the presence
of an unstable coronary syndrome fit well with these previous
observations.
Study limitations. This study has a number of limitations.
The analysis involved multiple comparisons and a relatively
small number of patients; thus, the possibility remains that the
observed association between low ascorbic acid concentration
and an unstable coronary syndrome is a chance finding.
Furthermore, the relatively high prevalence of unstable coro-
nary syndromes in the study patients could have led to an
overestimation of relative risk. It is important to point out that
the associations observed in this study do not necessarily imply
causality. It is possible that myocardial infarction is associated
with an inflammatory state or some other process that con-
sumes antioxidants and reduces their concentration in plasma.
However, such an effect is unlikely to explain our findings
because they were unchanged after patients with a recent
myocardial infarction were excluded. In addition, patients with
a recent myocardial infarction did not have lower ascorbic acid
levels than patients with unstable symptoms without a recent
infarction. It is also possible that higher antioxidant levels
might reflect a behavioral or dietary pattern that reduces risk
by other unmeasured factors such as level of physical activity.
Furthermore, it is possible that additional correlations between
antioxidant status and coronary artery disease might have been
demonstrated in a larger study or a different population.
Despite these limitations, our results support the hypothesis
that antioxidant status may be relevant to plaque activation
and the clinical expression of coronary artery disease rather
than affecting the overall extent of fixed disease. The results
provide a further rationale for ongoing trials of antioxidant
therapy in patients with coronary artery disease.
We gratefully acknowledge the technical support of Timi Mannion, RN and the
staff of the Boston Medical Center Cardiac Catheterization Laboratory.
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